ProKidney (PROK) Competitors $1.51 +0.05 (+3.42%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PROK vs. CNTA, RXRX, APGE, IBRX, WVE, MIRM, AKRO, TARS, AMPH, and IRONShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Centessa Pharmaceuticals Recursion Pharmaceuticals Apogee Therapeutics ImmunityBio Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine Centessa Pharmaceuticals (NASDAQ:CNTA) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do insiders and institutionals have more ownership in CNTA or PROK? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 41.5% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, CNTA or PROK? Centessa Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Does the media prefer CNTA or PROK? In the previous week, Centessa Pharmaceuticals had 14 more articles in the media than ProKidney. MarketBeat recorded 17 mentions for Centessa Pharmaceuticals and 3 mentions for ProKidney. ProKidney's average media sentiment score of 0.71 beat Centessa Pharmaceuticals' score of 0.46 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CNTA or PROK more profitable? ProKidney's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% ProKidney N/A N/A -10.24% Which has higher valuation and earnings, CNTA or PROK? ProKidney has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M330.14-$151.09M-$1.53-11.22ProKidneyN/AN/A-$35.47M-$0.55-2.75 Do analysts recommend CNTA or PROK? Centessa Pharmaceuticals currently has a consensus target price of $25.83, indicating a potential upside of 50.54%. ProKidney has a consensus target price of $4.50, indicating a potential upside of 198.01%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the MarketBeat Community favor CNTA or PROK? Centessa Pharmaceuticals received 21 more outperform votes than ProKidney when rated by MarketBeat users. However, 57.14% of users gave ProKidney an outperform vote while only 56.86% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes2956.86% Underperform Votes2243.14% ProKidneyOutperform Votes857.14% Underperform Votes642.86% SummaryProKidney beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$440.41M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-2.7546.7391.3417.19Price / SalesN/A411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book-0.313.894.794.78Net Income-$35.47M-$42.21M$120.07M$225.60M7 Day Performance-15.88%-2.14%-1.89%-1.24%1 Month Performance-12.97%4.21%11.45%3.36%1 Year Performance-22.16%18.40%30.61%16.58% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney2.0368 of 5 stars$1.51+3.4%$4.50+198.0%-15.6%$440.41MN/A-2.753Gap DownCNTACentessa Pharmaceuticals2.9997 of 5 stars$16.38-1.1%$25.83+57.7%+131.0%$2.16B$6.85M-10.8372Insider TradeRXRXRecursion Pharmaceuticals2.4151 of 5 stars$7.46+7.3%$9.25+24.0%-36.3%$2.14B$44.58M-4.85400News CoverageHigh Trading VolumeAPGEApogee Therapeutics2.5994 of 5 stars$47.07+5.8%$83.88+78.2%+92.5%$2.12BN/A-18.3991IBRXImmunityBio2.1332 of 5 stars$3.01+4.9%$17.38+477.2%-42.2%$2.10B$7.33M-3.36590Analyst ForecastWVEWave Life Sciences4.8841 of 5 stars$13.56+0.9%$22.22+63.9%+181.5%$2.07B$113.31M-12.11240MIRMMirum Pharmaceuticals4.0875 of 5 stars$42.32-0.3%$57.73+36.4%+34.8%$2.03B$307.03M-21.01140Positive NewsAKROAkero Therapeutics4.0824 of 5 stars$29.04+0.5%$46.83+61.3%+36.1%$2.03BN/A-7.7030Insider TradeTARSTarsus Pharmaceuticals0.3236 of 5 stars$51.58-1.8%$54.20+5.1%+164.4%$1.97B$17.45M-13.7850Positive NewsAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$40.90-3.2%$60.33+47.5%-33.1%$1.97B$644.40M14.081,761IRONDisc Medicine3.4713 of 5 stars$65.31+0.6%$87.50+34.0%+13.2%$1.94BN/A-16.3078Insider Trade Related Companies and Tools Related Companies CNTA Alternatives RXRX Alternatives APGE Alternatives IBRX Alternatives WVE Alternatives MIRM Alternatives AKRO Alternatives TARS Alternatives AMPH Alternatives IRON Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PROK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PROK Stock Alerts